Prevention of epiretinal membrane traction progression with topical indomethacin treatment: a case report and mini literature review

This case report explores the potential of 0.5% indomethacin eye drops (Indo0.5) in preventing the progression of epiretinal membrane traction. A 72-year-old patient with progressive vitreomacular traction was treated with Indo0.5, leading to a significant decrease in intraretinal cyst within 8 months, complete resorption after 16 months and full restoration of the retinal profile after 22 months. A mini literature review highlights the anti-inflammatory effects of indomethacin for various conditions affecting the anterior segment and suggests that the 0.5% concentration may also be effective in managing retinal inflammation. Indo0.5 could be a non-invasive option for slowing epiretinal membrane traction progression, supporting further research to optimize treatment strategies.